Vantictumab
Modify Date: 2024-04-06 14:16:52
Vantictumab structure
|
Common Name | Vantictumab | ||
|---|---|---|---|---|
| CAS Number | 1345009-45-1 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of VantictumabVantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma[1][2]. |
| Name | Vantictumab |
|---|
| Description | Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma[1][2]. |
|---|---|
| Related Catalog | |
| Target |
FZD1/2/5/7/8[1][2]. |
| References |
| No Any Chemical & Physical Properties |